Faculty - Experimental Therapeutics Ph.D. Track

Boyko S Atanassov, PhD, Assistant Professor, Bulgarian Academy of Sciences. Sofia Bulgaria.
Functions and regulation of deubiquitinating enzymes (USPs); Epigenetics; Regulation of gene expression, Molecular mechanism of cancer metastasis.

Dhyan Chandra, PhD, Associate Professor, Jawaharlal Nehru University
Heat-shock proteins and cell survival, metochondrial fragmentation and caspase activation, apoptosis signaling in cancer stem cells

Gokul Das, PhD, Associate Professor, Baylor College of Medicine
Tumor suppressor protein p53/transcriptional regulation/genomic damage, DNA repair, and cell cycle control/interaction between p53 and estrogen receptor signaling pathways

John Ebos, PhD, Assistant Professor, University of Toronto
Host- and tumor-mediated mechanisms of antiangiogenic drug resistance and their role in metastatic disease progression.

Michael E. Feigin, PhD, Assistant Professor, SUNY Stony Brook
Exploring the noncoding genome and GPCR signaling networks driving pancreas and breast cancer pathogenesis; 3D modeling of human tumors for therapeutic and mechanistic studies.

Gerald Fetterly, PhD, Adjunct Faculty, State University of New York at Buffalo

Barbara Foster, PhD, Associate Professor & Director of Graduate Studies, UC San Francisco
Prostate cancer; transgenic mouse models; prostate cancer/bone interaction; preclinical testing of novel therapeutic approaches for prevention and treatment of prostate cancer

David Goodrich, PhD, Professor, UC Berkeley
Elucidating molecular mechanisms underlying tumor suppression by the Rb1 gene, particularly in cell cycle regulation with the aim of targeting this pathway for cancer therapy

Elizabeth A. Griffiths, MD, Associate Professor, University of North Carolina School of Medicine
Cancer Epigenetics, Wnt biology, Acute Myeloid Leukemia 

Pamela Hershberger, PhD, Associate Professor, Case Western Reserve University
Exploiting nuclear hormone receptor signaling pathways in the prevention and treatment of lung cancer

Steven Hochwald, MD, Clinical Chief, Surgical Oncology, New York University School of Medicine
Research involves showing the direct interaction between FAK and IGF-1R signal transduction proteins in mammalian and cancer cells. Has patented the invention of novel small molecules that disrupt FAK and IGF-1R protein interactions.

Wendy Huss, PhD, Associate Professor, Baylor College of Medicine
Targeting the prostate tumor stem cell therapeutically in effort to eliminate the source of recurrent prostate cancer

Candace S. Johnson, PhD, Professor, President & CEO, RPCI, Ohio State University
Drug development of novel agents; preclinical tumor models; mechanistic studies on drugs with novel targets; steroid hormones and their potential as an antiproliferative agent and development of novel approaches in prostate cancer

Fengzhi Li, PhD, Associate Professor, Beijing
Mechanism of anti-apoptotic protein function and regulation in cancer cells

Ravindra K. Pandey, PhD, Professor, University of Rajasthan, Jaipur, India
Development of "Multifunctional Agents" for tumor imaging and therapy

Beth Pflug, PhD, Associate Professor, Georgetown University School of Medicine, Washington, DC.
The laboratory focuses on understanding tumor signaling and growth regulation in prostate cancer and uses this information to identify novel therapeutic and imaging targets for this disease.

Mukund Seshadri, DDS, PhD, Professor, Co-Director, Imaging Facility; State University of New York at Buffalo
Research is focused on the use of advanced imaging techniques such as magnetic resonance imaging, (MRI), computed tomography (CT) and optical molecular imaging techniques in preclinical and clinical studies.

Robert Straubinger, PhD, Professor, UC San Francisco
Cell biology and biophysics of membranes and membrane function; use of liposomal drug carriers to improve the efficacy of cancer therapeutics

Dean Tang, PhD, Professor, Chair of Pharmacology, Department of Pharmacology & Therapeutics, Wayne State University, Detroit, MI.
Understanding the molecular and cellular basis of tumor cell heterogeneity and developing novel therapeutics targeting cancer stem cells.

Xinjiang Wang, PhD, Assistant Professor, Weizmann Institute of Science, Rehovot, Israel
Identification of regulators of tumor cell growth control through biochemical and cell-based approaches; development of targeted cancer therapeutics

Anna Woloszynska-Read, PhD, Assistant Professor, University at Buffalo, Roswell Park Division
Research is focused on the role of genetic and epigenetic changes in bladder and prostate cancer in order to decipher the molecular landscape of the diseases, and to point to novel strategies for improved treatment. Research is also conducted in the area of prostate cancer racial health disparities. Specifically, the role of DNA methylation and vitamin D deficiency in aggressiveness of prostate cancer among African-American men.

Yuesheng Zhang, MD, PhD, Professor, Zhejiang University School of Medicine, Hangzhou, China, Johns Hopkins University School of Medicine, Baltimore, MD.
Non-enzymatic functions of prolidase, modulation of plasma protein degradation for development of protein therapeutics and disease biomarkers, EGFR- and HER2-directed cancer drug discovery and development.